Features associated with pulmonary arterial hypertension in Chinese hospitalized systemic lupus erythematosus patients

[1]  B. Maron,et al.  Molecular Mechanisms of Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension , 2016, International journal of molecular sciences.

[2]  Q. Fang,et al.  Predictors of health-related quality of life in patients with systemic lupus erythematosus associated pulmonary arterial hypertension. , 2016, Clinical and experimental rheumatology.

[3]  Q. Wang,et al.  Survival and prognostic factors of systemic lupus erythematosus-associated pulmonary arterial hypertension: A PRISMA-compliant systematic review and meta-analysis. , 2016, Autoimmunity reviews.

[4]  Q. Wang,et al.  Baseline Characteristics and Risk Factors of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus Patients , 2016, Medicine.

[5]  V. A. de Jesus Perez,et al.  Novel approaches to pulmonary arterial hypertension drug discovery , 2016, Expert opinion on drug discovery.

[6]  M. Landzberg,et al.  Anticoagulation in patients with pulmonary arterial hypertension: An update on current knowledge. , 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[7]  M. Gómez-Sánchez,et al.  Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: Prevalence and Predictors , 2016, The Journal of Rheumatology.

[8]  P. Zhu,et al.  Chinese SLE Treatment and Research group (CSTAR) registry VII: prevalence and clinical significance of serositis in Chinese patients with systemic lupus erythematosus , 2016, Lupus.

[9]  S. Joo,et al.  Determining the necessity for right heart catheterization in pulmonary hypertension associated with connective tissue diseases assessed by echocardiography , 2016, International journal of rheumatic diseases.

[10]  R. Phipps,et al.  Drug discovery in pulmonary arterial hypertension: attacking the enigmatic root of a deadly weed. , 2014, Drug discovery today.

[11]  M. Zhang,et al.  Chinese SLE Treatment and Research group (CSTAR) registry: II. Prevalence and risk factors of pulmonary arterial hypertension in Chinese patients with systemic lupus erythematosus , 2014, Lupus.

[12]  G. Ruiz-Irastorza,et al.  Pulmonary hypertension in systemic lupus erythematosus: prevalence, predictors and diagnostic strategy. , 2013, Autoimmunity reviews.

[13]  M. Eren,et al.  Comparison of mean platelet volume values among different causes of pulmonary hypertension. , 2012, Cardiology journal.

[14]  M. Humbert,et al.  Treatment of pulmonary arterial hypertension with targeted therapies , 2011, Nature Reviews Cardiology.

[15]  H. Ghofrani,et al.  Mechanisms of disease: pulmonary arterial hypertension , 2011, Nature Reviews Cardiology.

[16]  N. Nishimoto,et al.  The value of blocking IL-6 outside of rheumatoid arthritis: current perspective , 2011, Current opinion in rheumatology.

[17]  A. Chaouat,et al.  Calibrated automated thrombography demonstrates hypercoagulability in patients with idiopathic pulmonary arterial hypertension. , 2010, Thrombosis research.

[18]  G. Raskob,et al.  Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. , 2010, Chest.

[19]  M. Yigla,et al.  Coagulation and anticoagulation in pulmonary arterial hypertension. , 2009, The Israel Medical Association journal : IMAJ.

[20]  Alan C. Wilson,et al.  Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. , 2008, The Journal of rheumatology.

[21]  G. Simonneau,et al.  Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. , 2008, American journal of respiratory and critical care medicine.

[22]  Christine M. Miller,et al.  Plexiform-like lesions and increased tissue factor expression in a rat model of severe pulmonary arterial hypertension. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[23]  K. Lewis.  Pulmonary Arterial Hypertension in France: Results from a National Registry , 2007 .

[24]  Sanjay Mehta,et al.  Thrombotic arteriopathy and anticoagulation in pulmonary hypertension. , 2006, Chest.

[25]  J. Lima,et al.  The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). , 2005, Arthritis and rheumatism.

[26]  Adam Torbicki,et al.  Guías de Práctica Clínica sobre el diagnóstico y tratamiento de la hipertensión arterial pulmonar , 2005 .

[27]  A. Torbicki,et al.  Guidelines on diagnosis and treatment of pulmonary arterial hypertension , 2004 .

[28]  D. Gladman,et al.  Pulmonary hypertension in systemic lupus , 2004, Lupus.

[29]  D. Mccrory,et al.  Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. , 2004, Chest.

[30]  W. Seeger,et al.  Clinical classification of pulmonary hypertension. , 2001, Clinics in chest medicine.

[31]  L. Rubin,et al.  Primary pulmonary hypertension. , 1997, The New England journal of medicine.

[32]  R. Redberg,et al.  Five-year follow-up study of the prevalence and progression of pulmonary hypertension in systemic lupus erythematosus. , 1995, American heart journal.

[33]  W. Vainchenker,et al.  Effects of the recombinant hematopoietic growth factors interleukin-3, interleukin-6, stem cell factor, and leukemia inhibitory factor on the megakaryocytic differentiation of CD34+ cells. , 1993, Blood.

[34]  D. Sackett,et al.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. , 1992, Arthritis and rheumatism.

[35]  S. Burstein,et al.  Thrombocytopoiesis in normal and sublethally irradiated dogs: response to human interleukin-6. , 1992, Blood.

[36]  M. Petri,et al.  Pulmonary hypertension in systemic lupus erythematosus. , 1989, The Journal of rheumatology.

[37]  M. Koss,et al.  Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus. , 1984, Seminars in arthritis and rheumatism.

[38]  J F Fries,et al.  The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.

[39]  J. LeónCastro,et al.  [Primary pulmonary hypertension]. , 1971, Revista clinica espanola.